(B-175) Impact of Pharmaceutical Care on the Quality-Adjusted Life Years in Diabetic Foot Ulcer Patients - A Randomized Controlled Trial

Background: Diabetic foot ulcer is one of the reasons for hospitalization among diabetic patients. Diabetic foot ulcer constitutes a key cause of hospital admission, amputation, resultant adverse effects on living conditions, relationship status and health-related quality of life, and premature mortality among diabetic patients.

Objectives: The objective of study was to study the impact of pharmaceutical care on quality-adjusted life years in diabetic foot ulcer patients.

Methods: An open-label randomization-controlled trial was carried out for three years at a tertiary care charitable teaching hospital. The study's inclusion criteria were patients above 18 years, either gender, who are diagnosed with Diabetic foot ulcer. The patients were randomized into the general care and pharmaceutical care Group in a 1:1 ratio The socio-demographics, health-related quality of life and economic data were collected. The outcomes were assessed at baseline, 6th month and 12th month. A repeated measure of ANOVA was performed to analyze changes in the outcomes within groups.

Results: Out of 174 DFU patients, 87 patients each were allocated to pharmaceutical care and general care groups. At baseline, there was no statistical significant difference in health-related quality of life scores; in contrast, during 6th and 12th month, follow-ups showed a statistical significant improvement in domains like dependence/daily life (p=0.006), negative emotions (p=0.030) and bothered by ulcer care (p=0.024) in the pharmaceutical care group compared to general care group. The quality-adjusted life years for the DFU patients in the pharmaceutical care group was (-) Rs.9984.3 and (-) USD$.119.83 compared with the general care group.

Conclusions: The clinical pharmacist who provided structured pharmaceutical care services significantly positively impacted the health-related quality of life and economic outcomes in the pharmaceutical care group compared to the general care group among Diabetic foot ulcer patients.